Panretinal photocoagulation for proliferative diabetic retinopathy

New England Journal of Medicine

Volumn 365, Issue 16, 2011, Pages 1520-1526

  Bressler, Neil M ^a   Beck, Roy W ^b   Ferris III, Frederick L ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADULT; ARTICLE; CASE REPORT; DIABETIC RETINOPATHY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; LASER COAGULATION; MALE; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; OPHTHALMOSCOPY; PANRETINAL PHOTOCOAGULATION; PATHOLOGY; PRIORITY JOURNAL; RETINA; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; SLIT LAMP; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS FLOATERS;

EID: 80054737355     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct0908432     Document Type: Article

References (46)

1. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63. (Pubitemid 38456292)
2. Diabetes Control and Complications Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-83.
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
4. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98:Suppl:766-85.
5. National diabetes fact sheet, 2007: general information and national estimates on diabetes in the United States. (http://www.cdc.gov/diabetes/pubs/ pdf/ndfs-2007.pdf.)
6. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-96.
7. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005;353:839-41. (Pubitemid 41215495)
8. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298:902-16. (Pubitemid 47311296)
9. The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: diabetic retinopathy study report no. 14. Int Ophthalmol Clin 1994;27:239-53.
10. Ferris FL III. How effective are treatments for diabetic retinopathy? JAMA 1993;269:1290-1.
11. Diabetic Retinopathy Clinical Research Network. An observational study of the development of diabetic macular edema following scatter laser photocoagulation. (http://drcrnet.jaeb.org/Studies.aspx?RecID=142.)
12. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med 1996;124:164-9. (Pubitemid 26011617)
13. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-27.
14. Idem. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009;127:132-40.
15. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007;27:816-24. (Pubitemid 47479374)
16. Blankenship GW. A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1988;95:170-7. (Pubitemid 18057871)
17. Mensher JH. Anterior chamber depth alteration after retinal photocoagulation. Arch Ophthalmol 1977;95:113-6. (Pubitemid 8258621)
18. Liang JC, Huamonte FU. Reduction of immediate complications after panretinal photocoagulation. Retina 1984;4:166-70. (Pubitemid 14024897)
19. Yuki T, Kimura Y, Nanbu S, Kishi S, Shimizu K. Ciliary body and choroidal detachment after laser photocoagulation for diabetic retinopathy: a high-frequency ultrasound study. Ophthalmology 1997;104:1259-64. (Pubitemid 28048722)
20. Huamonte FU, Peyman GA, Goldberg MF, Locketz A. Immediate fundus complications after retinal scatter photocoagulation. I. Clinical picture and pathogenesis. Ophthalmic Surg 1976;7:88-99.
21. Blondeau P, Pavan PR, Phelps CD. Acute pressure elevation following panretinal photocoagulation. Arch Ophthalmol 1981;99:1239-41. (Pubitemid 11087071)
22. Zamir E, Anteby I, Merin S. Choroidal effusion causing transient myopia after panretinal photocoagulation. Arch Ophthalmol 1996;114:1284-5. (Pubitemid 26338867)
23. Lerner BC, Lakhanpal V, Schocket SS. Transient myopia and accommodative paresis following retinal cryotherapy and panretinal photocoagulation. Am J Ophthalmol 1984;97:704-8. (Pubitemid 14082956)
24. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50. (Pubitemid 24307211)
25. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71. (Pubitemid 26026196)
26. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. (Pubitemid 24356306)
27. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-61.
28. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22. (Pubitemid 28040457)
29. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
30. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46. (Pubitemid 34250056)
31. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9. (Pubitemid 20066716)
32. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-82. (Pubitemid 24350514)
33. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001;158:1161-72. (Pubitemid 32221808)
34. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol 1996;114:964-70. (Pubitemid 26271462)
35. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8. (Pubitemid 44318179)
36. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:155-8.
37. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-8. (Pubitemid 44442055)
38. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695.e1-1695.e15.
39. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006;34:802-3. (Pubitemid 44650158)
40. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8. (Pubitemid 43021723)
41. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064-77.
42. Bressler NB, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009;127:1566-71.
43. American Academy of Ophthalmology Retinal Panel. Preferred practice patterns. Diabetic retinopathy. San Francisco: American Academy of Ophthalmology, 2009. (http://one.aao.org/CE/PracticeGuidelines/SummaryBenchmark. aspx?cid=ea5c6d25-2ab9-4398-b00b-8efcb8cc5bc7.)
44. Chew EY, Ferris FL III, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the Early Treatment Diabetic Retinopathy follow-up study. Ophthalmology 2003;110:1683-9. (Pubitemid 37025423)
45. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
46. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.